Informed Prostate Cancer Patient Support

4 Health Technologies For Alternative Pain Relief | The Healthcare Guys

ADT Options for Prostate Cancer Come Out Even for Heart Safety | MedPage Today

CV Safety Study of Cancer Therapy Attracts Attention

Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study | Prostate Cancer and Prostatic Diseases

The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer - Wang - - The Prostate - Wiley Online Library

Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment - Sun - - The Prostate - Wiley Online Library

Chemotherapy and peripheral neuropathy | SpringerLink

Should I Be Worried About My Urine Color? - YouTube

Enlarged Prostate Doesn't Raise a Man's Odds for Cancer: Study

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223 | Prostate Cancer and Prostatic Diseases

Study on acupuncture in the treatment of painful diabetic peripheral neuropathy based on rs-fMRI: a protocol for systematic review and meta-analysis | BMJ Open

Enlarged Prostate Doesn't Raise a Man's Odds for Cancer

Paige's AI Diagnostic Tech is Revolutionizing Cancer Diagnosis - IEEE Spectrum : Cancer pathology today involves examining tissue samples under a microscope to make diagnoses. But tissues and disease markers can vary widely, so it's common for pathologists to seek a second opinion or conduct more tests. Paige's technology streamlines the process by digitizing it. The company has exclusive rights to tens of thousands of already-analyzed pathology slides from Memorial Sloan Kettering and has scanned them into its system to create a database of high-resolution images. The company's proprietary machine-learning system is trained to detect patterns in the images that correlate with disease prognosis. When a new tissue scan comes in, the system can classify it based on its training. Rather than phoning a colleague or doing extra testing, a pathologist can use the AI-based system to make decisions more quickly and easily, Grady says.

Cancer ABCs From Surviving To Thriving - How to Thrive with Cancer

Comparative Efficacy of Gabapentin and Duloxetine for Painful Diabetic Peripheral Neuropathy - Clinical Pain Advisor

Surveillance for Prostate Cancer Is on the Rise -- Do Men Stick It Out? | MedPage Today

Prostate Cancer Awareness Month - YouTube

Nucleoside antibiochemotherapy repressed the growth, chemoresistance, survival, and metastatic potentials of castration-resistant prostate cancer cells | bioRxiv

Patients helping researchers to advance treatments for prostate cancer -- ScienceDaily

New treatment halts prostate cancer progression: report

(11464) Inoreader - Interferon-γ Increases Sensitivity to Chemotherapy and Provides Immunotherapy Targets in Models of Metastatic Castration-Resistant Prostate Cancer

Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk | Prostate Cancer and Prostatic Diseases

Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis | Prostate Cancer and Prostatic Diseases

Fear of prostate cancer recurrence post-surgery | THE "NEW" PROSTATE CANCER INFOLINK prostatecancerinfolink.net Fear of prostate cancer recurrence post-surgery 4-5 minutes Posted on August 19, 2021 by Sitemaster A new paper by Meissner et al. has reported important, long-term data on fear of recurrence and biochemical progression of prostate cancer among a large cohort of German patients undergoing radical prostatectomy. This appears to be the largest such study to date. The results of this study are based on a total of 2,417 survivors from the multicenter German Familial Prostate Cancer Database all of whom had been initially treated by radical prostatectomy.  These patients completed the Fear of Progression Questionnaire – Short Form twice : on average at 7 years after radical prostatectomy (T1 in 2010) and again at follow-up 9 y

Whole-pelvic radiation therapy for high-risk patients | THE "NEW" PROSTATE CANCER INFOLINK prostatecancerinfolink.net Whole-pelvic radiation therapy for high-risk patients 5-7 minutes Posted on August 19, 2021 by Sitemaster The decision about whether or not to treat the entire pelvic lymph node area along with the prostate (called whole pelvic radiation therapy or WPRT) or to treat just the prostate with a margin around it (called prostate-only radiation therapy or PORT) has long been a matter of judgment. Now we have proof of its benefit in most high-risk patients. Murthy et al. reported the results of “POP-RT,” a randomized clinical trial conducted among 224 high-risk and very high-risk patients treated at the Tata Memorial Hospital in Mumbai, India between 2011 to 2017. What sets this trial apart from previous trials that had eq

Early ADT May Not Up OS in Prostate Cancer With PSA Relapse

EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy | Prostate Cancer and Prostatic Diseases

The association between occupational asbestos exposure with the risk of incidence and mortality from prostate cancer: a systematic review and meta-analysis | Prostate Cancer and Prostatic Diseases

Can Working Out Slow Prostate Cancer Progression? | MedPage Today medpagetoday.com Can Working Out Slow Prostate Cancer Progression? by Mike Bassett, Staff Writer, MedPage Today August 19, 2021 5-7 minutes Oncology > Prostate Cancer — Intense exercise improved markers of biochemical progression in patients on active surveillance Rigorous exercise not only boosted cardiorespiratory fitness, but also improved indicators of prostate cancer biochemical progression in patients undergoing active surveillance, according to results of a randomized trial. Patients participating in a 12-week high-intensity interval training (HIIT) regimen saw an increase in peak oxygen consumption (VO 2 ) -- the study's primary

Swedish Prostate Cancer Screening Method Cuts MRIs, Biopsies

Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity | Neurology

Death of Spouse Could Raise Odds for Prostate Cancer

Convolutional Neural Networks for Automated Classification of Prostate Multiparametric Magnetic Resonance Imaging Based on Image Quality - Cipollari - - Journal of Magnetic Resonance Imaging - Wiley Online Library

Health‐Related Quality of Life in Cancer Survivors with Chemotherapy‐Induced Peripheral Neuropathy: A Randomized Clinical Trial - Bao - - The Oncologist - Wiley Online Library : The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.

Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort - Lonergan - 2021 - The Prostate - Wiley Online Library

Novel Blood-Based Test Could Bolster MRI-Based Prostate Cancer Screening | MedPage Today

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumor cells -- ScienceDaily

New blood test improves prostate cancer screening -- ScienceDaily

Timing of initiation of ADT for men with biochemical progression after first-line surgery | THE "NEW" PROSTATE CANCER INFOLINK

Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics - Nandalur - - The Prostate - Wiley Online Library

Rethinking risk stratification for radiation therapy | THE "NEW" PROSTATE CANCER INFOLINK

Prostate Cancer: Why Early Detection Matters

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand | Science Advances

Frontiers | Role of Specialized Pro-Resolving Mediators in Neuropathic Pain | Pharmacology

When Is ADT Right for Biochemically Recurrent Prostate Cancer? | MedPage Today

The Leading Edge of Active Surveillance for Prostate Patients and Urologists - YouTube

PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer | Prostate Cancer and Prostatic Diseases

'Routine' Use of Focal Therapy for Prostate Cancer in Next 5 Years

Androgen Blockers Likely Boost Survival in Older Men With Nonmetastatic CR Prostate Cancer

The role of testing in prostate cancer treatment - YouTube

Prostate cancer screening using prostate-specific antigen, a multiplex blood-test, MRI and targe... - YouTube

Men Should Ejaculate at Least 21 Times a Month To Slash Their Prostate Cancer Risk

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC - YouTube

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC - YouTube

ASCO 2021: Precision and molecular reporting for prostate cancer - YouTube

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prosta... - YouTube

ASCO 2021: Latest on PARPi and other treatments for mCRPC - YouTube

mCRPC: Latest developments in diagnostics and combination therapies - YouTube

Developments in metastatic hormone-sensitive prostate cancer - YouTube

Orgovyx - The Newest Hormone Treatment (ADT) for Prostate Cancer — Cancer ABCs

Vitamin B12 Fights Nerve Pain And Defends Your Heart And Brain

Researchers uncover a way to harness the power of immunotherapy for advanced prostate cancer -- ScienceDaily sciencedaily.com Researchers uncover a way to harness the power of immunotherapy for advanced prostate cancer 5-6 minutes It's a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy? Researchers led by the University of Michigan Rogel Cancer Center started with a simple thread: an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells. This is the most challenging type of prostate cancer -- advanced disease that has become resistant to hormone-based treatment. From there, they continued to untangle the web to discover multiple levels of cellular processes that were preventing the immune system from mounting a response. Break past them with this inhibitor and suddenly